At a glance
- Originator Schering-Plough
- Class Antiasthmatics; Antirheumatics; Piperazines
- Mechanism of Action Neurokinin 1 antagonists; Neurokinin 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 18 Dec 2003 No development reported - Preclinical for Asthma in USA (unspecified route)
- 30 Apr 2001 New profile
- 30 Apr 2001 Preclinical development for Asthma in USA (Unknown route)